What is the treatment for fungal sinusitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Fungal Sinusitis: Comprehensive Management Guide

Classification and Clinical Recognition

Fungal sinusitis presents in three distinct forms requiring fundamentally different treatment approaches: allergic fungal sinusitis (non-invasive), fungal ball/mycetoma (non-invasive), and invasive fungal sinusitis (acute, chronic, or granulomatous). 1, 2

The classification determines survival, with invasive forms carrying 50-80% mortality rates even with treatment, making rapid differentiation critical 1

Key Clinical Patterns to Recognize:

Non-Invasive Forms:

  • Allergic fungal sinusitis: Caused by Bipolaris, Curvularia, Aspergillus, and Dreschlera species; presents with thick eosinophilic mucin and nasal polyposis 1, 2
  • Fungal ball: Typically unilateral maxillary or sphenoid sinus involvement with dense fungal concretions 2, 3

Invasive Forms:

  • Acute invasive fungal sinusitis: Rapid progression <4 weeks in immunocompromised patients (neutropenia, hematologic malignancies, poorly controlled diabetes, AIDS, transplant recipients, those on steroids/chemotherapy) 1, 4
  • Presenting symptoms: fever, rhinorrhea, diplopia, facial pain, headache—often nonspecific 1, 4
  • Critical endoscopic finding: Pale mucosa progressing to ulceration and necrosis 1

Diagnostic Approach

Imaging Strategy:

CT without contrast is the initial imaging modality of choice for all suspected fungal sinusitis. 1, 3

CT findings by type:

  • Fungal ball: Hyperattenuation within involved sinus (though nonspecific) 1
  • Invasive disease: Bone erosion, periantral fat infiltration, pterygopalatine fossa involvement, septal ulceration, orbital extension 1
  • A 7-variable CT model (infiltration of periantral fat, pterygopalatine fossa, nasolacrimal duct/lacrimal sac, bone dehiscence, septal ulceration, orbital involvement) with any 2 positive findings demonstrates 88% sensitivity for invasive disease 1

MRI with and without IV contrast is superior for:

  • Detecting orbital and intracranial complications (thrombosis, cavernous sinus involvement, infarction, hemorrhage) 1, 3
  • Evaluating vascular complications (pseudoaneurysm, arterial thrombosis/dissection) from angioinvasive fungi 1

Definitive Diagnosis:

Biopsy with histopathological examination remains the gold standard, demonstrating invasive fungi in sinonasal mucosa, vessels, and bone for invasive forms. 1, 3


Treatment by Type

Fungal Ball (Mycetoma):

Surgical removal via simple antrostomy is the definitive treatment; antifungal medications are NOT indicated. 2, 3

  • More extensive procedures (antrostomy combined with inferior meatal window) may be needed in select cases and result in better outcomes with no residual inflammation 2
  • Recurrence rate: 3-4% with longer follow-up, necessitating surveillance 2, 3

Allergic Fungal Sinusitis:

Complete surgical exenteration with mucosal preservation is the primary treatment, followed by mandatory postoperative steroid therapy. 2

Surgical approach:

  • Endoscopic sinus surgery to remove all allergic mucin and fungal debris 2, 5
  • Preserve mucosa to allow normal function to resume 2

Medical management (essential postoperatively):

  • Oral and nasal corticosteroids are mandatory to control the inflammatory process 2, 5
  • Postoperative antifungal therapy role remains unproven, though anecdotal reports suggest potential benefit as adjunct 2
  • Consider immunotherapy and antimicrobial agents for bacterial superinfection 5

Critical pitfall: Unilateral polypoid disease may mimic tumors (inverted papilloma); always biopsy 2


Invasive Fungal Sinusitis:

Invasive fungal sinusitis requires aggressive combined therapy: immediate surgical debridement PLUS systemic antifungal therapy PLUS reversal of immunosuppression. 2, 3, 4

Surgical Management:

Aggressive debridement of ALL necrotic sinonasal tissue is essential and non-negotiable. 2, 4

  • Endoscopic approaches demonstrate superior survival (64%) compared to open procedures (54%) 2
  • Complete removal of infected and necrotic tissue is critical 2
  • Goals: diagnostic sampling and debridement 4
  • Repeat debridement often necessary based on clinical response 4

Medical Management:

Systemic antifungal therapy is mandatory and must be initiated immediately. 2, 3, 4

First-line antifungal therapy:

  • Liposomal amphotericin B is the recommended first-line empiric therapy 2, 4
  • Voriconazole may be superior for Aspergillus species 2, 3, 6
  • Newer azoles offer better bioavailability and less toxicity 2
  • Continue treatment for at least 6 weeks after surgical intervention 3

Voriconazole dosing (for invasive aspergillosis): 6

  • Loading dose: IV formulation on Day 1
  • Maintenance: 200 mg oral every 12 hours (achieves exposure similar to 3 mg/kg IV)
  • Continue IV for at least 7 days before switching to oral
  • Administer at least 1 hour before or after meals 6

Reversal of Immunosuppression:

Equally or more important than surgery and antifungals is reversal of underlying immune suppression. 4

  • Discontinue or reduce immunosuppressive medications when possible 4
  • Optimize diabetic control 4
  • Consider immune-stimulating therapies (though require additional study) 4

Critical Pitfall:

AVOID oral corticosteroids in invasive fungal disease due to additive immunosuppressive effects, EXCEPT when needed to reduce edema with orbital or cerebral involvement. 2


Prognostic Factors in Invasive Disease

Patient-specific mortality predictors: 2

  • Best survival: Diabetic patients (50% survival) 2
  • Worst survival: Aplastic anemia (20%), renal/hepatic failure (24%), neutropenia (29%) 2
  • Hematologic malignancies: Hazard ratio 3.7 for mortality 2
  • Recent chemotherapy: HR 2.3 2
  • Bone marrow transplant: HR 2.5 2

Follow-up and Surveillance

Regular endoscopic examination is mandatory to detect early recurrence, particularly in invasive forms. 2, 3

  • CT imaging for surveillance of extent and recurrence 3
  • Histopathological examination essential for classification 3
  • Continued smoking after surgery is associated with significantly worse long-term outcomes 2

Treatment Algorithm Summary

  1. Suspect fungal sinusitis in immunocompromised patients with sinusitis symptoms, unilateral disease, or treatment-refractory chronic sinusitis
  2. Obtain CT without contrast immediately
  3. Perform nasal endoscopy looking for pale/necrotic mucosa (invasive) vs. thick mucin (allergic)
  4. Biopsy for definitive diagnosis and fungal culture
  5. If invasive disease suspected: Start liposomal amphotericin B immediately, arrange urgent surgical debridement, reverse immunosuppression
  6. If fungal ball: Schedule surgical removal via antrostomy; no antifungals needed
  7. If allergic fungal sinusitis: Complete surgical exenteration followed by mandatory corticosteroid therapy

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Fungal Sinusitis Treatment Approach

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Fungal Sinus Infections Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Allergic fungal sinusitis: diagnosis and treatment.

Current opinion in otolaryngology & head and neck surgery, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.